Santa Monica Observer - Community, Diversity, Sustainability and other Overused Words

By Stan Greene
Observer Staff Writer 

83% of Covid-19 patients off ventilators in ten days, when administered Stem Drug. Usually only 9% come off ventilators after Covid19 ARDS.

Australian Pharma Co Reports Miraculous Results With Use of Its Drug on Advanced Covid-19 Patients

 

April 29, 2020

Quora

A Covid-19 patient on a ventilator. Mesoblast Company claims that with remestemcel-L administered within the first 5 days, 83% of the patients survived and came off ventilators within ten days. Otherwise, the survival rate is about 9%.

An Australian pharmaceutical company claims an 83% recovery rate among Covid-19 patients on ventilators.

The study was conducted at Mount Sinai Hospital in New York City in March and April, on Covid-19 patients on ventilators. ARDS Covid-19 patients on ventilators ordinarily experience a 9% survival rate.

When remestemcel-L is administered within the first 5 days, 83% of the patients survived and came off ventilators within ten days. A press release posted on Globenewswire Friday reported these results.

It's unclear why the mainstream media has not picked up the story about remestemcel-L. If true, it's a coronavirus game changer. Mesoblast's press release is below, we have reached out to Mesoblast Company's representatives to verify the story. We will update this story with their response.

Key points:

83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated with two infusions of Mesoblast's allogeneic cell therapy remestemcel-L within the first five days under emergency compassionate use at New York City's Mt Sinai hospital during the period March-April 2020

75% (9/12) have successfully come off ventilator support within a median of 10 days

These results contrast with only 9% of ventilator-dependent COVID-19 patients being able to come off ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at two major referral hospital networks in New York during the same time period1,2

This compassionate use treatment experience has informed the design of the clinical protocol for the randomized, placebo-controlled Phase 2/3 trial of remestemcel-L in ventilator-dependent COVID-19 moderate/severe ARDS patients across North America

NEW YORK, April 24, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome (ARDS) treated during the period March-April 2020 with two intravenous infusions of Mesoblast's allogeneic mesenchymal stem cell product candidate remestemcel-L within the first five days. 75% (9/12) have successfully come off ventilator support at a median of 10 days. At this time, seven have been discharged from the hospital. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at New York City's Mt Sinai hospital.

In contrast, only 9% (38/445) of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support when treated with standard of care during March/April 2020.1 Moreover, there was 88% mortality with only 12% survival (38/320) among ventilator-dependent COVID-19 patients at a second major referral hospital network in New York City during the same period.2 These poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and moderate/severe ARDS.3

Mesoblast Chief Executive Dr Silviu Itescu stated: "The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients."

Mesoblast Chief Medical Officer Dr Fred Grossman said: "There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS." https://finance.yahoo.com/news/83-survival-covid-19-patients-100010532.html

References

1 Petrilli CM et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. MedRxiv 2020 doi: https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf

2 Richardson S et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020. doi:10.1001/jama.2020.6775

3 Liu Y et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. MedRxiv 2020; https://www.medrxiv.org/content/10.1101/2020.04.08.20057794v1.full.pdf

About Mesoblast

Quora

A Covid-19 patient on a ventilator. Mesoblast Company claims that with remestemcel-L administered within the first 5 days, 83% of the patients survived and came off ventilators within ten days. Otherwise, the survival rate is about 9%.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast's Biologics License Application to seek approval of its product candidate RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA). Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. If approved, RYONCIL is expected to be launched in the United States in 2020 for pediatric steroid-refractory acute GVHD. Two products have been commercialized in Japan and Europe by Mesoblast's licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

 

Reader Comments
(0)

 
 

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2020

Rendered 08/02/2020 07:22